##semicolon##
гиперпролактинемия, аденомы гипофиза, иммуногистохимия, рак молочной железы.##submission.citations##
Akirov A., et al. Breast cancer risk in patients with dopamine agonist-treated hyperprolactinemia: a cohort study. J Clin Endocrinol Metab. 20 25;110(5):e1584-e1592. https://doi.org/10.1210/c linem/dgad084
Bird S.B. Toxicologic mechanism and the increased breast cancer risk associated with antipsychotic-induced hyperprolactinemia. ScienceDirect. 2025. https://www.sciencedirect.com/science/arti-cle/pii/S2214750025000459
Kresovich J.K., Guranich C., Houghton S., et al. Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies. Breast Cancer Res. 2024;26(1):169. https:// doi.org/10.1186/s13058-024-01922-6
Shams A., et al. Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment. Discov Oncol. 2024;15:797. https://doi.org/10.1007/s1267 2-024-01701-x
Taipale H., et al. Relative risk of breast cancer associated with prolactin-increasing antipsychotics: a population-based study. J Clin Psychiatry. 2024;85(2):e13564. https://doi.org/10.4088/JCP.2 1m14192